Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)

J.E Rosenberg; E Heath; R Perez; J Merchan; J Lang; D Ruether; D Petrylak; R Sangha; D.C Smith; S Sridhar; E Gartner; M Vincent; R Chu; B Anand; F Donate; A Melhem-Bertrandt; J Zhang

doi:10.1093/annonc/mdw373.16

Back

Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)

Journal article

Open access

Peer reviewed

Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)

J.E Rosenberg, E Heath, R Perez, J Merchan, J Lang, D Ruether, D Petrylak, R Sangha, D.C Smith, S Sridhar, …

Annals of oncology, Vol.27, pp.vi273-vi273

2016-10-01

DOI: https://doi.org/10.1093/annonc/mdw373.16

Files and links (1)

url

https://doi.org/10.1093/annonc/mdw373.16View

Published (Version of record) Open

Metrics

39 Record Views

4 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.233 Pelvic & Renal Disorders; 1.233.690 Bladder Cancer
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)
Creators: J.E Rosenberg - Genitourinary Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
E Heath - Medical Oncology, Karmanos Cancer Institute, Detroit, MI, USA
R Perez - Medical Oncology, University of Kansas Cancer Center, Fairway, KS, USA
J Merchan - Medical Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
J Lang - Genitourinary Oncology, UW Carbone Cancer Center, Madison, WI, USA
D Ruether - Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada
D Petrylak - Medical Oncology, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, USA
R Sangha - Oncology, University of Alberta Cross Cancer Institute, Edmonton, AB, Canada
D.C Smith - Internal Medicine and Urology, University of Michigan, Ann Arbor, MI, USA
S Sridhar - Oncology, Princess Margaret Hospital, Toronto, ON, Canada
E Gartner - Development, Seattle Genetics, Inc., Seattle, WA, USA
M Vincent - Clinical Research and Development, Agensys, Inc., Santa Monica, CA, USA
R Chu - Development, Agensys Inc., Santa Monica, CA, USA
B Anand - Development, Agensys Inc., Santa Monica, CA, USA
F Donate - Translational Research, Agensys Inc., Santa Monica, CA, USA
A Melhem-Bertrandt - Clinical Research, Astellas Pharma, Northbrook, IL, USA
J Zhang - Medical Oncology, H. Lee Moffitt Cancer Center University of South Florida, Tampa, FL, USA
Publication Details: Annals of oncology, Vol.27, pp.vi273-vi273
Publisher: Elsevier Ltd
Academic Unit: UMMG Dept of Medicine - Hematology/Oncology; Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991031598084902976